Atlas Trials

Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC

Clinical trial NCT03379441 · UNKNOWN

Trial details

NCT number
NCT03379441
Sponsor
University of Turin, Italy
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Non Small Cell Lung Cancer Patients
Start date
2018-01-01
Primary completion
2023-01-01
Enrollment
126

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.